Live Breaking News & Updates on Md Laval University

Stay updated with breaking news from Md laval university. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TRILUMINATE Deep Dive Clarifies 'Meaningful' QoL Gains With Tricuspid TEER

The benefits observed with edge-to-edge repair were greater in patients with worse baseline status. ....

New York , United States , Suzannev Arnold , Dee Wang , Wayne Batchelor , Anita Asgar , Boehringer Ingelheim Eli Lilly , Roxana Mehran , Suzanne Baron , Yousif Ahmad , Falls Church , University Of Missouri , Md Montreal Heart Institute , Journal Of The American College Cardiology , Md Saint Luke Mid America Heart Institute , Md Laval University , Phd Yale School Of Medicine , Md Henry Ford Health System , Vascular Institute , Saint Luke , Mid America Heart Institute , Missouri Kansas City , Kansas City , Massachusetts General Hospital , Henry Ford Health System , American College ,

Pre-TAVI PCI Linked to More Late Bleeding, With Implications for Survival

The findings should remind operators to consider whether PCI is absolutely needed, and to take care with antithrombotic choices. ....

San Sebastiano , Felice Gragnano , Paolo Calabr , Marisa Avvedimento , Phd Laval University Quebec Heart Lung Institute , Md Laval University , Phd University Of Campania Luigi Vanvitelli , Valve Academic Research , Josep Rod , Quebec Heart , Lung Institute , Campania Luigi Vanvitelli , San Sebastiano Hospital , Cardiovascular Interventions , Laval University ,

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

June 03, 2021
Accumulating data make clear the detrimental effect of moderate aortic stenosis (AS) in patients who have heart failure with reduced ejection fraction (HFrEF), a new study suggests, and they point toward the potential for improving survival after TAVI.
Compared with patients who had HFrEF but not moderate AS, those with the combination of both had greater risk for mortality at 3 years (HR 2.98; 95% CI 2.08-4.31), as well as for the composite of HF hospitalization and mortality (HR 2.34; 95% CI 1.72-3.21). Additionally, those who had TAVI over the follow-up period survived longer than those on medication alone.
Senior author Marie-Annick Clavel, PhD (Laval University, Quebec, Canada), said the while there is consensus that moderate aortic stenosis is not benign, optimal management for the subset of patients with both HF and moderate aortic stenosis is unclear. However, she said current thinking seems to be moving away from “wait-and-see” approaches to ....

United States , Nilayk Patel , Sammy Elmariah , Guillaume Jean , Marie Annick Clavel , Journal Of The American College Cardiology , Md Laval University , Phd Laval University , Laval University , American College , Provide More , Massachusetts General Hospital , ஒன்றுபட்டது மாநிலங்களில் , கிலௌம் ஜீன் , இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல் , ம்ட் லாவள் பல்கலைக்கழகம் , லாவள் பல்கலைக்கழகம் , அமெரிக்கன் கல்லூரி , வழங்க மேலும் , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை ,

Moderate Aortic Stenosis and HFrEF Combo Portend Poor Survival, Study Finds

Valve replacement, particularly TAVI, showed promise as an early intervention, but a randomized trial is ongoing. ....

United States , Nilayk Patel , Sammy Elmariah , Guillaume Jean , Marie Annick Clavel , Journal Of The American College Cardiology , Md Laval University , Phd Laval University , Laval University , American College , Provide More , Massachusetts General Hospital , ஒன்றுபட்டது மாநிலங்களில் , கிலௌம் ஜீன் , இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல் , ம்ட் லாவள் பல்கலைக்கழகம் , லாவள் பல்கலைக்கழகம் , அமெரிக்கன் கல்லூரி , வழங்க மேலும் , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை ,

Excluded from Pivotal Trials, Low-risk Complex Patients Warrant Caution

January 22, 2021
A significant proportion of real-world patients with severe aortic stenosis and low surgical risk have an additional valvular or CV condition that was never accounted for in pivotal trials of TAVI versus SAVR and that requires a serious discussion by the heart team, Canadian research shows.
In the study of primarily low-risk patients who underwent SAVR between 2000 and 2019, 40.8% had at least one of the following conditions: non-tricuspid aortic valve (NTAV), severe coronary artery disease (SevCAD), concomitant mitral/tricuspid valve (CMTV), or concomitant ascending aorta replacement (CAAR). All four of those patient subgroups were routinely excluded from RCTs of TAVI compared with SAVR. ....

New York , United States , Alberto Alperi , Gilbert Tang , Poonam Velagapudi , Md Mount Sinai Health System , Journal Of The American College Cardiology , Ms University Of Nebraska Medical Center , Md Laval University , Laval University , American College , Mount Sinai Health System , Holistic Approach , Nebraska Medical Center , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , கில்பர்ட் டாங் , பூனம் வேலகப்பூடி , ம்ட் ஏற்ற சினை ஆரோக்கியம் அமைப்பு , இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல் , செல்வி பல்கலைக்கழகம் ஆஃப் நெப்ராஸ்கா மருத்துவ மையம் , ம்ட் லாவள் பல்கலைக்கழகம் , லாவள் பல்கலைக்கழகம் , அமெரிக்கன் கல்லூரி , ஏற்ற சினை ஆரோக்கியம் அமைப்பு , முழுமையான அணுகுமுறை ,